An interventional study of TAVR in Aortic Valve Stenosis, sponsored by IHF GmbH - Institut für Herzinfarktforschung. Active, not recruiting at 15 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by IHF GmbH - Institut für Herzinfarktforschung · Not applicable, Interventional, and Treatment
Mehilli J, Steffen J, Rudolph T, Haum M, Giannini C, Stark K, Ince H, Conradi L, Joner M, Schafer A, Karcher AK, Landt M, Adam M, Thiele H, Geisler T, Jochheim…PubMed 42663358 ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 191 studies in Aortic Valve Stenosis with a site in Germany — 39 open to participants now, 58 under way, 3 of them phase 3. Aortic Valve Stenosis · Germany.
Among the 191 studies in Aortic Valve Stenosis with a site in Germany, this one is the 61st largest by enrollment of the 93 interventional ones that give a count, is one of 12 that started in 2019, is one of 82 with no phase, reaches primary completion later than 36 of the 57 other live ones, and was the 110th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →39 of the 191 studies in Aortic Valve Stenosis with a site in Germany are open now. Recruiting first, the newest first:
Erasmus Medical Center · Sites in Germany, Netherlands
Ages 70+
IHF GmbH - Institut für Herzinfarktforschung · Sites in Germany
Ages 18+
Idoven 1903 S.L. · Sites in Germany
Ages 18+ · Healthy volunteers
Institut für Pharmakologie und Präventive Medizin · Sites in Germany
Ages 18+
Ceric Sàrl · Sites in Germany, Austria, Estonia and 11 more countries
Ages 65–75
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
191 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 12 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is close to the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.
Median enrollment 220 across the 93 interventional studies, 300 across the 98 observational. Of the 109 that completed or were terminated, 28 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 191 have an industry lead sponsor. The 10 most frequent:
IHF GmbH - Institut für Herzinfarktforschung is the lead sponsor of 16 studies on the registry; 4 are open to participants now.
IHF GmbH - Institut für Herzinfarktforschung has 2 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
7 of the studies in Aortic Valve Stenosis with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07479992Idoven 1903 S.L.Multicenter Study for the Validation of Willem AI: Aortic StenoSis Early Diagnosis With AI-electrocardiogram Study | 2027-01 |
| NCT06493994University of LuebeckMyval TransAXillary Transcatheter Aortic Valve Replacement Multicenter Clinical Registry | 2027-01-30 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
| NCT07520591Cardiawave SAValvosoft Outcomes Registry for Real-World Evidence | 2027-06-30 |
| NCT05603520Heinrich-Heine University, DuesseldorfPhenotyping Heterogeneity and Regionality of the Aorta | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 191 studies in Aortic Valve Stenosis with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Aim of this study is to evaluate whether microsurgical repair or replacement of the aortic valve is a treatment option for a subgroup of patients suffering from aortic Stenosis.
Stenosis of the aortic valve leads to a narrowing of the valve, consequently to low blood flow from the heart into the Aorta, and is associated with symptoms like fatigue, breathlessness, dizziness, fainting, and chest pain. For many of the patients suffering from severe aortic stenosis surgical or catheter-assisted repair or replacement of the damaged aortic valve has been proven to be a safe and effective treatment option.
Probably about 20-30% of patients suffering from severe aortic stenosis display a deviation from the usually observed disease pattern: These patients do not show the typical high pressure difference between the left ventricle (heart chamber) and the aorta (transvalvular gradient; "paradoxical" low flow/low gradient aortic stenosis). For these patients it is not yet clear, if microsurgical repair of the aortic valve (transcatheter aortic valve repair - TAVR) should be a treatment option as well.
REBOOT-PARADOX evaluates whether TAVR is advantageous compared to optimal medical Treatment alone for patients suffering from paradoxical aortic stenosis. Two thirds of the participating patients will be treated by TAVR, one third will receive medical Treatment alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be treated by transcatheter aortic valve repair (TAVR).
Device: TAVR
Patients will receive optimal medical treatment alone.
Repair of defective aortic valve by microsurgical Intervention.
Time to death
All-cause mortality
Time frame: 24 months after last-patient-in
Cardiovascular mortality
Death because of cardiovascular events
Time frame: 5 years after index treatment
Re-hospitalization due to heart failure
Number of hospital stays after randomization
Time frame: 5 years after index treatment
Incidence of neurological events - incidence of strokes
Number of strokes
Time frame: 5 years after randomization
Incidence of neurological Events - incidence of transient ischaemic attacks
Number of transient ischaemic attacks
Time frame: 5 years after randomization
Cardiac functionality - left ventricular function
Echocardiographic measurement of left ventricular ejection fraction in %
Time frame: 5 years after randomization
Cardiac functionality - aortic valve hemodynamics
Measurement of aortic pressure in mmHg
Time frame: 5 years after randomization
Patients' quality of life
EQ5D-score in %
Time frame: 5 years after randomization
Device reliability
Number of reinterventions (TAVR arm only)
Time frame: 5 years after randomization
Plan to share: No
Started Jul 2019 (actual). Primary completion is estimated for Sep 2027, 97 months after the start.
Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 97 months is above that.
Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.
Completion moved once since we started tracking on Sep 25, 2026: Mar 2028 → Sep 2027, on Nov 9, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Mehilli J, Steffen J, Rudolph T, Haum M, Giannini C, Stark K, Ince H, Conradi L, Joner M, Schafer A, Karcher AK, Landt M, Adam M, Thiele H, Geisler T, Jochheim…PubMed 42663358 ↗
Mehilli J, Steffen J, Rudolph T, Haum M, Giannini C, Stark K, Ince H, Conradi L, Joner M, Schafer A, Karcher AK, Landt M, Adam M, Thiele H, Geisler T, Jochheim…PubMed 42663358 ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IHF GmbH - Institut für Herzinfarktforschung